Agreement - August 10, 2016
Cellaviva in new agreement
Diamyd’s associated company Cellaviva has signed an agreement regarding the European distribution rights for a stem cell product developed by StemBioSys, a privatetly held biomedical company based in Texas, USA. The agreement entails that Cellaviva becomes the exclusive distributor for StemBioSys’ products in Sweden and Denmark with non-exclusive rights covering the rest of Europe. The […]
Acquisition - April 20, 2016
Diamyd increases investment in Cellaviva
Diamyd Medical has announced that the company has increased its investment in the associated company Cellaviva with an additional SEK 1.3 million. The investment is made within the framework of a convertible loan of SEK 2.7 million, mainly directed at existing shareholders. The convertible loan will, among others, be used to finance Cellaviva’s development of existing service […]
Uncategorized - August 1, 2015
Cellaviva launches new service
Diamyd Medical’s associated company Cellaviva launches service for private family saving of stem cells. Diamyd Medical has announced that the their associated company Cellaviva AB on September 1 launches its service in which expecting parents in Sweden can save stem cells from their newborn child. Stem cells from the baby’s umbilical cord are saved and stored […]
Collaboration - May 11, 2015
Biobank Could Help Diamyd with Diabetes Vaccine
Diamyd, which is developing a vaccine against type 1 diabetes, now owns 39 percent of Cellaviva, Sweden’s first commercial biobank for stem cells. Diamyd made the investment because of the potential resource for research. “We believe in stem cells. Among other things, we hope that in the future we will be able to use them […]
